Advertisement

Fact file: What is the smoking cessation drug Champix/Chantix?

TORONTO – A Toronto Star investigation claims that 24 Canadians who have taken the drug Champix to quit smoking have committed suicide since the drug hit the market in 2007.

The investigation also looked into 450 cases of people who reportedly took the smoking cessation drug Champix in Canada and have alleged to have suffered from severe psychiatric side effects, which include aggression, depression and suicidal thoughts.

“Canadians expect the drugs they take have been rigorously [tested] for safety and efficacy before they are allowed on the market and are actively monitored once they are approved,” says Health Canada senior media relations officer Sean Upton in a statement to Global News.

“Health Canada takes this responsibility very seriously and has put in place a world-class system for both the pre-market approval and post-market surveillance of health products.”

Story continues below advertisement

According to Pfizer Canada, more than four million Champix prescriptions have been written since the drug was approved for use by Health Canada in 2007.

Get breaking Canada news delivered to your inbox as it happens so you won't miss a trending story.

Get breaking National news

Get breaking Canada news delivered to your inbox as it happens so you won't miss a trending story.
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy.

Varenicline, marketed as Chantrix in the United States and Champix in Canada, is a prescription medication used to treat smoking addictions.

The FDA states that varenicline works by blocking the effects of nicotine from smoking on the brain. Manufacturers of the drug claim Champix can relieve the craving and withdrawal symptoms associated with stopping smoking.

When used as directed on the label, Health Canada says that the benefits of Champix continue to outweigh the risks.

“We continue to monitor this product using all sources of available information for any additional adverse reactions of concern that may not already be labelled or not labelled sufficiently to reflect the current risk/benefit profile,” says Upton.

In 2007, the US Food and Drug Administration (FDA) declared Chantix must carry a black box warning-the agency’s strongest warning label-after it continued to receive several public reports that patients taking the drug were experiencing hostility, depressed moods, agitation and suicidal thoughts or actions.

Australia’s regulatory authority for therapeutic goods, the Therapeutic Goods Administration, released a report in 2010 stating there have been 206 suicide-related events in people taking Champix, including 15 suicides.

Story continues below advertisement

Champix’s product monograph on Pfizer Canada currently states that, “Some people have had changes in behavior, hostility, agitation, aggression, depressed mood, and suicidal thoughts or actions while taking CHAMPIX to help them quit smoking.”

As with most severe side-effect warnings, patients are advised to stop taking the medication and seek emergency medical care should they observe unusual thoughts, feelings or behaviours.

Global News spoke to Pfizer Canada via e-mail who stated that while patients should be aware that neuropsychiatric side-effects have occurred in patients taking Champix-with or without a history of psychiatric disorder-currently “there is no reliable scientific evidence to demonstrate that CHAMPIX causes serious neuropsychiatric events.”

Pfizer says that while reported side effects are important, “they have significant limitations and do not establish causality between a medicine and the event reported.”

Sponsored content

AdChoices